Biocurious company information, Employees & Contact Information

Biocurious: Tag-team leadership helps sleep device maker Somnomed regain its bite Stockhead

Biocurious: Control Bionics says outwitting the world’s richest man is a no-brainer Stockhead

Biocurious: Behind Optiscan’s quest to ditch biopsies and bring pathology into the modern era Stockhead

Biocurious: Noxopharm has the ‘burning fire’ of inflammation squarely in its sights Stockhead

Biocurious: Five years post-pandemic, the Covid ‘hero’ stocks forge a new path Stockhead

Biocurious: ASX drug developers see silver lining in FDA’s interventionist approach Stockhead

Biocurious: With psychedelic therapies gaining cred, Tryptamine offers patients and investors the trip of a lifetime Stockhead

Biocurious: Nexsen’s upcoming IPO highlights need for diagnostics speed Stockhead

Biocurious: The cannabis stocks that stand out in a field of weeds Stockhead

Biocurious: In clinical terms, Singular Health ensures the right arm knows what the left arm is doing Stockhead

Biocurious: With fresh grant funding, Emvision’s Emu stroke device won’t take a step backwards Stockhead

Biocurious: Rhythm gets into the groove of predicting and preventing cancer Stockhead

Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected Stockhead

Biocurious: Clever Culture Systems has a lot on its ‘plate’ as it revolutionises quality control in drug making Stockhead

Biocurious: Nyrada looks to change the treatment landscape for brain and heart disorders Stockhead

Biocurious: In a torrid capital raising climate, early-stage biotechs turn to alternative funding Stockhead

Biocurious: CSL’s R&D chief says drug development is like falling in love Stockhead

Biocurious: Lumos shines a light on the post-pandemic rapid diagnosis sector Stockhead

Biocurious: FDA approval remains the Holy Grail for ASX life science stocks Stockhead

Biocurious: With Mayne Pharmaceuticals under takeover offer, who’s next? Stockhead

Biocurious: Behind Race Oncology’s quest to prevent chemo from being worse than the disease Stockhead

Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy Stockhead

‘A challenge to learn’ American Society for Biochemistry and Molecular Biology

Biocurious: Armed with a lucky payment number, Control Bionics plots its US expansion Stockhead

Biocurious: Drug developers are hedging their bets on long and winding approval journey Stockhead

Biocurious: Having gained FDA approval, Orthocell is ready to ‘rock and roll’ in the US Stockhead

BioCurious – a Hackerspace for Biology! National Archives (.gov)

Biocurious: EBR Systems is on a ‘glide path’ to FDA approval for its novel heart device Stockhead

Feeling Biocurious? How To Get Your DIY Bio On KQED

Biohackers aim to open Silicon Valley lab for group research and lessons The Mercury News

‘Biocurious’ about biotech? Here are 10 must-follow Twitter accounts statnews.com

Biocurious: While other biotechs scratch around for cash, Clinuvel is accused of having too much Stockhead

Biocurious: EZZ’s tennis sponsorship serves up 300 million Chinese viewers Stockhead

Biocurious: No sweat as Botanix tackles the world’s third-biggest skin disorder Stockhead

Biocurious: Hut Hut Hut! The growing list of ASX biotechs waiting for the FDA to call the start of play Stockhead

Biocurious: With its ‘molecular Lego’ approach, Arovella is building hope for cancer patients one brick at a time Stockhead

Biocurious: Lung imager Cyclopharm is breathing easy in the US market Stockhead

Biocurious: Cracking the code on Paradigm’s valuation enigma Stockhead

Biocurious: Consumer health minnow Wellnex Life gears up for company-making Eurotrip Stockhead

Biocurious: With its pre-budget 'wish list', Ausbiotech prepares to bat for the sector in Canberra Stockhead

Biocurious: Sometimes an effective therapy lies not just with the drug, but how it is delivered Stockhead

Biocurious: IPO candidate Nexsen Biotech tackles global infant killer with early diagnosis tool Stockhead

Biocurious: Avita Medical gets skin in more games with its wider wound care push Stockhead

Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial Stockhead

Biocurious: Stiff competition aside, cryopreserver Vitrafy has the ingredients for success Stockhead

65 U.S. Biotech and Pharma Incubators Genetic Engineering and Biotechnology News

Biocurious: Forgotten trans-Tasman 'small Big Pharma' takes on the big boys with a niche strategy Stockhead

Bio Curious: ‘Best-kept secret in Australian healthcare’ spruiks its telehealth credentials Stockhead

Hackers breach biology to transform life into building material PBS

Biocurious: Painchek’s aged care and infant market expansion plans could be much-needed salve Stockhead